CardioTech Receives FDA Approval For Export Of Second Graft Size For CardioPass Clinical Trial
CardioTech International, Inc. (AMEX: CTE), a leading developer and manufacturer of advanced biomaterials for a broad range of medical devices, announced that it has received the necessary U.S. Food and Drug Administration (”FDA”) approval to export its 4mm graft in further support of the ongoing European clinical trial of CardioPass? , the Company’s proprietary synthetic coronary bypass graft.
More: continued here
Filed under: Cardiovascular on July 16th, 2008